A practical reference on PPARδ: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-17 and is reviewed periodically as new material appears.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
=== Brand names === Nefazodone has been marketed under a number of brand names including Dutonin (ATTooltip Austria, ESTooltip Spain, IETooltip Ireland, UKTooltip United Kingdom), Menfazona (ESTooltip Spain), Nefadar (CHTooltip Switzerland, DETooltip Germany, NOTooltip Norway, SETooltip Sweden), Nefazodone BMS (ATTooltip Austria), Nefazodone Hydrochloride Teva (USTooltip United States), Reseril (ITTooltip Italy), Rulivan (ESTooltip Spain), and Serzone (AUTooltip Australia, CATooltip Canada, USTooltip United States).
Meanwhile, Duterte's ICC withdrawal was challenged before the Supreme Court by three petitions filed by the Philippine Coalition for the ICC, the Integrated Bar of the Philippines, and opposition senators; though the Court in March 2021 ultimately dismissed all three cases on the grounds that the petitioners were unable to establish legal standing to challenge the ICC withdrawal, the court ruled that the president has no "unbridled authority" to withdraw from treaties. The ICC, on September 16, 2021, eventually authorized a formal investigation into the war on drugs in the Philippines, focusing on crimes committed between 2016 and March 2019. In response, the Philippine government in November 2021 requested a deferral of the probe, which was suspended by the ICC to assess the request. Four days before Duterte left office, however, ICC prosecutor Karim Ahmad Khan requested the pre-trial chamber of the ICC to immediately resume the investigation after concluding that the deferral request was "not warranted". The succeeding Marcos administration initially declined to allow any ICC probe in the country due to sovereignty issues; however, due to tensions between the Duterte and Marcos political families, the Marcos administration is seen as increasingly open to cooperating with the ICC. Duterte stated he remained unfazed at the threat of arrest, saying he would rather "die first" before facing a foreign court. Salvador Panelo, who served as Duterte's chief legal counsel, alleged that Duterte's political opponents were using the ICC as a "political and propaganda apparatus".
Ari is "over the moon" when Mia tells him she is pregnant, but they decide to keep the news to themselves until they learn more about the pregnancy because of their history, which includes several miscarriages. An initial worry occurs when Mia is told her hormone levels are high, but the pair later learn that everything is fine with the baby and Mia is actually further along in the pregnancy than they first thought. An Inside Soap columnist wondered whether it would be "a smooth road to parenthood" for the couple this time round. During the show's 2021 mid-season finale, Mia is one of three characters involved in a life-threatening car accident. She and Dean go out to pick up Nikau, who has been stranded out of town, but on the way back Dean swerves to avoid hitting a kangaroo and the car is left hanging from a cliff edge. Mia does not suffer any serious injuries, but she miscarries. At the hospital, Ari is "stunned" when he sees Mia arrive and learns what has happened to their baby. He later breaks down in Tane's arms. The couple struggle in the wake of the miscarriage, as they morn the loss of their baby. Mia is cold towards Ari and struggles to talk to him, as he tries to help her settle back home after she is discharged. Ari continues to confide in Tane and he questions where his relationship with Mia stands. The couple agree not to try for another baby and instead they turn to adoption. Samson thought that the storyline made sense for Ari and Mia, as they had been focused on having a child and it was "the next logical step for them".
Sources: en.wikipedia.org
== WADA proscription == In 2015, Radwa Arafa Abd Elsalam, an athlete from Egypt, underwent a doping control where ractopamine was identified in the sample. Elsalam was sanctioned by the Egyptian Anti-Doping Organisation (EGY-NADO) with a two year ineligibility period for non-intentional presence of a prohibited substance, in violation of Article 2.1 of the EGY-NADO rules. While not mentioned by name in the 2015 Prohibited List, ractopamine was determined to — much like clenbuterol, another β2-adrenergic agonist — constitute an Other Anabolic Agent prohibited under S1.2. Elsalam appealed the decision, claiming that ractopamine is used in the meat industry overseas, so she must have inadvertently consumed food contaminated with ractopamine. EGY-NADO accepted her appeal, reduced the sanction to six months, and provided the World Anti-Doping Agency (WADA) with records pertaining to the case. WADA filed an appeal with the Court of Arbitration for Sport (CAS) against EGY-NADO and Elsalam with respect to the appealed decision. WADA asserted ractopamine was "undisputed[ly]" an Other Anabolic Agent, that "[i]t is not sufficient for an athlete merely to make protestations of innocence and suggest that the prohibited substance must have entered her body in inadvertently", and that "her explanations are nothing more than mere speculation".
In 1959 Ernst Freese coined the terms "transitions" or "transversions" to categorize different types of point mutations. Transitions are replacement of a purine base with another purine or replacement of a pyrimidine with another pyrimidine. Transversions are replacement of a purine with a pyrimidine or vice versa. There is a systematic difference in mutation rates for transitions (Alpha) and transversions (Beta). Transition mutations are about ten times more common than transversions.
The leader of the Libyan Islamist Fighting Group, Abdel-Hakim Belhaj, stated that while being tortured in Abu Salim prison, he was forced to give information regarding Libyans living in the United Kingdom, who were then allegedly arbitrarily arrested by the British government.
=== Outcomes === Following barotrauma of the ears or lungs from diving the diver should not dive again until cleared by a diving doctor. After ear injury examination will include a hearing test and a demonstration that the middle ear can be autoinflated. Recovery can take weeks to months.
Sources: en.wikipedia.org
===== Lipid nanoparticles ===== Lipid nanoparticles (LNPs) are based on liposome-like structures that are typically made of an aqueous center surrounded by a lipid shell. A subset of liposomal structures used for delivery drugs to tissues rest in large unilamellar vesicles (LUVs) which may be 100 nm in size. LNP delivery mechanisms have become an increasing source of encasing nucleic acids and may include plasmids, CRISPR and mRNA. The first approved use of lipid nanoparticles as a drug delivery mechanism began in 2018 with the siRNA drug patisiran, developed by Alnylam Pharmaceuticals. Dicerna Pharmaceuticals, Persomics, Sanofi and Sirna Therapeutics also worked to bring RNAi therapies to market. Other recent applications include two FDA approved COVID-19 vaccines: mRNA-1273, developed by Moderna. and BNT162b, developed by a collaboration between Pfizer and BioNtech. These two vaccines use lipid nanoparticles to deliver antigen mRNA. Encapsulating the mRNA molecule in lipid nanoparticles was a critical breakthrough for producing viable mRNA vaccines, solving a number of key technical barriers in delivering the mRNA molecule into the host cell as distributed through apolipoprotein E (apoE) in the low-density lipoprotein receptor (LDLR). In December 2020, Novartis announced that positive results from phase III efficacy studies deemed inclisiran was a treatment for heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD).
Recent research efforts are being devoted to the homogeneous recycling by Grouped Actinides Extraction (GANEX), which consists in a previous uranium recovery (GANEX 1) and a successive group separation of plutonium, neptunium, americium and curium actinide ions (GANEX 2).
== Neutralization == In the duodenum, gastric acid is neutralized by sodium bicarbonate. This also blocks gastric enzymes that function optimally in the acid range of pH. The secretion of bicarbonate from the pancreas is stimulated by secretin. This polypeptide hormone gets activated and secreted from so-called S cells in the mucosa of the duodenum and jejunum when the pH in the duodenum falls below 4.5 to 5.0. The neutralization is described by the equation:
== History == In 2005, the Siuzdak Lab created an open-source tool named XCMS in the programming language R. Noticing the need for a more accessible, graphical data processing tool they created the cloud-based XCMS Online in 2012. The ability for users to stream data directly from instruments while being acquired was added in 2014. Also in that year a commercial version named XCMS Plus (owned by Mass Consortium Corporation) was released and, in 2015, SCIEX became a reseller. In 2017 it was shown that XCMS Online could be used in a systems biology workflow. One year later, in the absence of a publicly available alternative, a version of XCMS Online and METLIN-MRM was released with the ability to perform multiple reaction monitoring (MRM) and generate MRMs. In 2026, a new version of METLIN-MRM was introduced that enabled a more refined means of generating MRM isotope removal, in-source fragment removal and spline-fitting at multiple collision energies. The accuracy of uMRM was demonstrated on over 300 molecular standards as compared to traditional approaches.
== Welfare considerations during farmed insect rearing == As with other livestock animals, a variety of welfare concerns can manifest during the rearing and slaughter of insects. The 5 Domains framework can be used to broadly categorize these areas of possible concern into four functional domains (nutrition, environment, behavior, and physical health) which then influence the mental domain of the animal's welfare state. As the insect industry is very new, and there are few animal welfare scientists dedicated to studying its livestock, there is little guidance or infrastructure dedicated to improving farmed insect welfare. Further, just as with farmed vertebrates, species-specific guidance is needed to maintain high welfare for each species of insects that is farmed. Recently, several comprehensive and open access review papers have been published that cover the likely welfare concerns for black soldier flies (Hermetia illucens), yellow mealworms (Tenebrio molitor), and three species of farmed crickets (Acheta domesticus, Gryllus bimaculatus, Gryllodes sigillatus), as well as some work on the housefly (Musca domestica). The major, currently known areas of welfare concern during rearing are organized below by functional domain and largely focus on the most farmed insects: black soldier flies, yellow mealworms, and farmed crickets.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.